DDX53 and neoplasm: They also demonstrated that this anti-tumor effect was cancer-specific: when mice that experienced CT26 tumor regression upon VT1093M + VT1092M treatment were rechallenged with CT26 cells or H22 hepatocellular carcinoma cells, only H22 formed tumors [154].